Bolt Biotherapeutics, Inc. (BOLT)
BOLT Stock Price Chart
Explore Bolt Biotherapeutics, Inc. interactive price chart. Choose custom timeframes to analyze BOLT price movements and trends.
BOLT Company Profile
Discover essential business fundamentals and corporate details for Bolt Biotherapeutics, Inc. (BOLT) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
5 Feb 2021
Employees
52.00
Website
https://www.boltbio.comCEO
William P. Quinn
Description
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.
BOLT Financial Timeline
Browse a chronological timeline of Bolt Biotherapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 11 Nov 2025
EPS estimate is -$5.08.
Earnings released on 14 Aug 2025
EPS came in at -$4.46 surpassing the estimated -$6.40 by +30.31%, while revenue for the quarter reached $1.80M , beating expectations by +100.22%.
Stock split effective on 9 Jun 2025
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 12 May 2025
EPS came in at -$5.80 surpassing the estimated -$6.80 by +14.71%, while revenue for the quarter reached $1.22M , beating expectations by +59.22%.
Earnings released on 24 Mar 2025
EPS came in at -$7.60 matching the estimated -$7.60, while revenue for the quarter reached $10.00K , missing expectations by -98.73%.
Earnings released on 12 Nov 2024
EPS came in at -$0.40 falling short of the estimated -$0.36 by -11.11%, while revenue for the quarter reached $1.14M , beating expectations by +44.43%.
Earnings released on 13 Aug 2024
EPS came in at -$0.56 falling short of the estimated -$0.54 by -3.70%, while revenue for the quarter reached $1.28M , beating expectations by +43.26%.
Earnings released on 14 May 2024
EPS came in at -$0.28 surpassing the estimated -$0.51 by +45.10%, while revenue for the quarter reached $5.27M , beating expectations by +156.02%.
Earnings released on 21 Mar 2024
EPS came in at -$0.47 matching the estimated -$0.47, while revenue for the quarter reached $2.09M , beating expectations by +21.96%.
Earnings released on 9 Nov 2023
EPS came in at -$0.43 surpassing the estimated -$0.49 by +12.24%, while revenue for the quarter reached $2.53M , beating expectations by +42.82%.
Earnings released on 7 Aug 2023
EPS came in at -$0.48 surpassing the estimated -$0.53 by +9.43%, while revenue for the quarter reached $1.43M , missing expectations by -24.58%.
Earnings released on 11 May 2023
EPS came in at -$0.45 surpassing the estimated -$0.49 by +8.16%, while revenue for the quarter reached $1.83M , beating expectations by +39.39%.
Earnings released on 29 Mar 2023
EPS came in at -$0.53 surpassing the estimated -$0.63 by +15.87%, while revenue for the quarter reached $1.41M , beating expectations by +14.25%.
Earnings released on 10 Nov 2022
EPS came in at -$0.58 falling short of the estimated -$0.56 by -3.57%, while revenue for the quarter reached $2.11M , beating expectations by +71.71%.
Earnings released on 10 Aug 2022
EPS came in at -$0.61 surpassing the estimated -$0.68 by +10.29%, while revenue for the quarter reached $1.39M , beating expectations by +178.60%.
Earnings released on 12 May 2022
EPS came in at -$0.64 surpassing the estimated -$0.71 by +9.86%, while revenue for the quarter reached $813.00K , beating expectations by +62.60%.
Earnings released on 30 Mar 2022
EPS came in at -$0.73 falling short of the estimated -$0.66 by -10.61%, while revenue for the quarter reached $508.00K , beating expectations by +35.47%.
Earnings released on 9 Nov 2021
EPS came in at -$0.63 matching the estimated -$0.63, while revenue for the quarter reached $752.00K , beating expectations by +50.40%.
Earnings released on 12 Aug 2021
EPS came in at -$0.64 falling short of the estimated -$0.38 by -68.42%.
Earnings released on 13 May 2021
EPS came in at -$0.86 falling short of the estimated -$0.64 by -34.37%.
Earnings released on 31 Mar 2021
EPS came in at -$0.97 .
Earnings released on 5 Feb 2021
EPS came in at -$0.71 .
BOLT Stock Performance
Access detailed BOLT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.